CKD-331 / Chong Kun Dang - LARVOL DELTA

A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2) (clinicaltrials.gov) - P1 | N=66 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed | Trial completion date: Apr 2024 ➔ Jan 2024

Trial completion • Trial completion date • Dyslipidemia • Metabolic Disorders

A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2) (clinicaltrials.gov) - P1 | N=66 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial • Dyslipidemia • Metabolic Disorders

A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391 (clinicaltrials.gov) - P1 | N=69 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed

Trial completion • Dyslipidemia • Metabolic Disorders

Study to Evaluate the Safety and Pharmacokinetics of CKD-331 (clinicaltrials.gov) - P1 | N=47 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed

Trial completion • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia (clinicaltrials.gov) - P3 | N=228 | Recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P3 trial • Dyslipidemia • Metabolic Disorders

A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391 (clinicaltrials.gov) - P1 | N=66 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial • Dyslipidemia • Metabolic Disorders

Phase 1 Study to Evaluate the Safety and Pharmacokinetics of CKD-331 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial • Dyslipidemia • Hypertension • Metabolic Disorders